Vancouver, Canada – August 5, 2025 – Augurex Life Sciences, a leader in autoimmune biomarker-based diagnostics, today announced its participation in the Association of Medical Laboratory Immunologists (AMLI) 38th Annual Meeting, taking place August 14–17 at the Hyatt Regency Minneapolis. This premier event brings together leaders in laboratory medicine, clinical immunology, and diagnostic innovation to advance patient care in autoimmune and inflammatory diseases.
Augurex will be exhibiting at Booth #21, where attendees can learn more about 14-3-3eta, a diagnostic and modifiable prognostic biomarker that enhances both early detection and ongoing management of rheumatoid arthritis (RA). By aiding in diagnosis, including in seronegative patients, and supporting the monitoring of disease progression and treatment response, 14-3-3eta helps clinicians make more informed and personalized decisions across the RA care continuum.
As part of its commitment to advancing biomarker-driven diagnostics, Augurex is hosting an expert-lead industry lunch seminar during the AMLI 2025 program:
- Title: The Role of 14-3-3eta in the Diagnosis and Management of Rheumatoid Arthritis
- Speaker: Stanley J. Naides, MD, FACP, FACR (Labcorp)
- Date: Friday, August 15 | 12:00-1:30 PM
- Location: AMLI 2025 Annual Meeting | Hyatt Regency Minneapolis
This presentation will highlight the role of 14-3-3eta in RA-related inflammation, its robust technical validation, and its clinical utility in supporting earlier diagnosis and longitudinal monitoring to improve patient outcomes.
For more information about the event, visit: AMLI 2025
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s lead diagnostic test, which detects the 14-3-3eta protein, is available as JOINTstat® in Canada and Great Britain, and is an important tool in the diagnosis and management of inflammatory diseases, including rheumatoid arthritis. The analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex ASRs, available as SPINEstat™ in Canada and Great Britain, expands Augurex’s biomarker-informed diagnostic autoimmune solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, and which, if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.
Media Contact
Nima Mazinani
(604) 674-8231
media@augurex.com